Loading organizations...
§ Private Profile · New York City, NY, USA
AI-driven chemistry platform developer automating small-molecule discovery and manufacturing for pharma and biotech.
Excelsior Sciences is a New York City-based biotechnology company that develops an artificial intelligence-driven chemistry platform to automate small-molecule drug discovery and manufacturing. The organization utilizes modular components known as smart bloccs for machine-readable synthesis, enabling closed-loop drug discovery and the rapid production of compounds for pharmaceutical testing. By automating these complex chemical processes, the enterprise aims to optimize drug development timelines for biotech customers and facilitate the reshoring of pharmaceutical supply chains from overseas. To scale its proprietary technology and expand its initial team of chemists, the company secured $95 million in Series A funding, comprising a $25 million New York State grant and a $70 million private round co-led by Deerfield Management, Khosla Ventures, and Sofinnova Partners. Excelsior Sciences was founded in 2024 by Michael Foley, Jana Jensen, Marty Burke, and Bartosz Grzybowski.
Excelsior Sciences has raised $95.0M across 1 funding round.
Excelsior Sciences has raised $95.0M in total across 1 funding round.
Excelsior Sciences has raised $95.0M across 1 funding round. Most recently, it raised $95.0M Grant / Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 3, 2025 | $95M Grant | James Flynn, Nessan Bermingham, Edward Kliphuis | Mitú, ELI Lilly And Company, Illinois Ventures, Hope Knight | Announced |
Excelsior Sciences has raised $95.0M in total across 1 funding round.
Excelsior Sciences's investors include James Flynn, Nessan Bermingham, Edward Kliphuis, MIT, Eli Lilly and Company, Illinois Ventures, Hope Knight.